Aerie Pharmaceuticals Company Profile (NASDAQ:AERI)

Analyst Ratings

Consensus Ratings for Aerie Pharmaceuticals (NASDAQ:AERI) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $45.71 (163.48% upside)

Analysts' Ratings History for Aerie Pharmaceuticals (NASDAQ:AERI)
Show:
DateFirmActionRatingPrice TargetActions
6/2/2016Cantor FitzgeraldInitiated CoverageBuy$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/5/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2015JMP SecuritiesBoost Price TargetOutperform$39.00 -> $49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2015Needham & Company LLCBoost Price TargetBuy$27.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2015Stifel NicolausBoost Price TargetBuy$30.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/5/2015Piper Jaffray Cos.Reiterated RatingBuy$7.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2015MLV & Co.Reiterated RatingBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Aerie Pharmaceuticals (NASDAQ:AERI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016Q216($0.74)N/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2016Q116($0.64)($0.72)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2016Q415($0.72)($0.64)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.66)($0.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.70)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.62)($0.70)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.46)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014($0.40)($0.54)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014($0.34)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.35)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2014Q413($0.25)($0.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/4/2013Q313($0.25)($10.81)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aerie Pharmaceuticals (NASDAQ:AERI)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Aerie Pharmaceuticals (NASDAQ:AERI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aerie Pharmaceuticals (NASDAQ:AERI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/22/2016Foresite Capital Fund Ii, L.P.Major ShareholderBuy250,000$17.50$4,375,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Anand MehraDirectorSell425,000$33.64$14,297,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell175,000$31.11$5,444,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell23,620$30.86$728,913.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell80,724$30.05$2,425,756.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,704$30.36$1,509,013.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,441$30.36$1,501,028.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Anand MehraDirectorSell800,000$26.00$20,800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Group Holdings (Sbs) Advis TpgInsiderSell1,300,000$25.97$33,761,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell1,000,000$25.17$25,170,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell500,000$25.05$12,525,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Anand MehraDirectorSell323,932$16.00$5,182,912.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Iv L.P. AcpMajor ShareholderSell300,000$16.00$4,800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Gerald CagleDirectorBuy1,854$15.07$27,939.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Brian LevyInsiderBuy6,000$10.00$60,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Iv L.P. AcpMajor ShareholderBuy110,000$10.00$1,100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Richard J RubinoCFOBuy10,000$10.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Thomas A MitroCOOBuy5,000$10.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Vicente Anido JrCEOBuy28,000$10.00$280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Anand MehraDirectorBuy285,000$10.00$2,850,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Lifesciences Ii L.P. ClarusMajor ShareholderBuy321,000$10.00$3,210,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aerie Pharmaceuticals (NASDAQ:AERI)
DateHeadline
07/27/16 06:30 AMAerie Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Wednesday, August 3, 2016 - [Business Wire] - Aerie Pharmaceuticals, Inc. , , announced today that its second quarter 2016 financial results will be released after the market closes on Wednesday, August 3, 2016.
07/25/16 02:26 PMAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Stock Rises, Analysts ... - Review Fortune
07/25/16 07:06 AMHC Trending Hot Stocks: Aerie Pharmaceuticals Inc (NASDAQ:AERI) Vertex Pharmaceuticals Incorporated (NASDAQ ... - share market updates (press release)
07/23/16 07:32 AMEquity Roundup: Stock Performance Focus on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Press Telegraph
07/23/16 07:32 AMIs $50 Price Target Attainable For Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)? - Investor Newswire
07/21/16 02:20 PMAerie Pharmaceuticals Inc (NASDAQ:AERI) Stock Technicals Hit Strength - CML News
07/21/16 02:20 PMBroker Outlook For Aerie Pharmaceuticals, Inc. (AERI) - Fiscal Standard
07/20/16 02:55 PMAerie Pharmaceuticals, Inc. (NASDAQ:AERI): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 10:28 AMStock Moving Lower for the Month; Investor Update on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Engelwood Daily
07/20/16 10:28 AMHow Analysts Rated Aerie Pharmaceuticals Inc (NASDAQ:AERI) Last Week? - Consumer Eagle
07/18/16 02:20 PMAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Wall Street Analyst Recommendation Outlook - TGP
07/18/16 07:10 AMStock in Positive Territory for the Quarter: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Engelwood Daily
07/17/16 07:05 AMShares Moving Down on the Week: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Engelwood Daily
07/16/16 10:44 AMShares Experiencing a Downtrend: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - TGP
07/15/16 06:36 PMStrong Sell Calls For Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) At 0 - Investor Newswire
07/14/16 11:11 AMAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 11:11 AMAerie Pharmaceuticals Inc Stock Momentum at Critical Inflection Point - CML News
07/13/16 10:24 AMShares Losing Ground for the Month; Investor Alert on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Engelwood Daily
07/13/16 05:31 AMAERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
07/12/16 02:22 PMHow Many Aerie Pharmaceuticals Inc (NASDAQ:AERI)'s Analysts Are Bearish? - Consumer Eagle
07/11/16 02:20 PMWall Street Ratings and Target Price Views on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Telanagana Press
07/11/16 02:20 PMAerie Pharmaceuticals Inc Realized Volatility Hits Elevated Level - CML News
07/11/16 07:07 AMNext Weeks Broker Price Targets For Aerie Pharmaceuticals, Inc. (AERI) - Fiscal Standard
07/08/16 07:31 PMIs $50 Within Reach For Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)? - Investor Newswire
07/06/16 02:20 PMCan Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Improve on the Earnings Front? - Engelwood Daily
07/06/16 02:20 PMAerie Pharmaceuticals Inc.: Aerie Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - The Wall Street Transcript
07/06/16 07:06 AMStock Tracking Down This Month; Investor Alert on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Engelwood Daily
07/06/16 06:41 AMAerie Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - July 6, 2016 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class ...
07/04/16 07:07 AMAerie Pharmaceuticals Incorporated (NASDAQ:AERI) Sellers Covered 4.81% of Their Shorts - Press Telegraph
07/02/16 10:02 AMAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Expected to Reach Highs Of $50 - Investor Newswire
07/01/16 10:18 AMAerie Pharmaceuticals, Inc. (AERI) Updated Price Targets - FTSE News
06/30/16 02:21 PMAerie Pharmaceuticals, Inc. (AERI) Current Analyst Ratings - Fiscal Standard
06/29/16 02:17 PMAerie Pharmaceuticals Inc. (AERI) Jumps 6.41% on June 28 - Equities.com
06/28/16 07:33 AMCovering the Bases on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): Where is the Stock Going? - Press Telegraph
06/27/16 07:06 AMAerie Pharmaceuticals, Inc. (AERI) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 07:34 PMStrong Sell Calls Recommendations For Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) At 0 - Investor Newswire
06/24/16 10:16 AMNew Broker Ratings For Aerie Pharmaceuticals, Inc. (AERI) - FTSE News
06/23/16 03:47 PMAerie Pharmaceuticals : Patent Issued for 6-Aminoisoquinoline Compounds (USPTO 9365518)
06/23/16 10:05 AMAERIE PHARMACEUTICALS INC : Other Events (form 8-K)
06/22/16 02:21 PMAerie Pharmaceuticals, Inc. (NasdaqGM:AERI) Stock Momentum at Critical Inflection Point - CML News
06/22/16 05:31 AMAERIE PHARMACEUTICALS INC Files SEC form 8-K, Other Events -
06/21/16 07:06 AMRecently Issued Stock Ratings For Aerie Pharmaceuticals, Inc. (AERI) - Fiscal Standard
06/20/16 02:19 PMEarnings in Focus: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - iStreetWire
06/19/16 02:19 PMGlobal Diabetic Retinopathy Pipeline Report 2016 - Review of 41 Therapeutics Companies & Drug Profile Activity - Research and Markets
06/19/16 07:04 AMThis Weeks Broker Views For Aerie Pharmaceuticals, Inc. (AERI) - Fiscal Standard
06/18/16 07:03 AMStrong Buy Calls Count For Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) At 4 - Investor Newswire
06/17/16 02:18 PMCompany Update (NASDAQ:AERI): Aerie Pharmaceuticals Inc Completes Enrollment of Rocket 4 Phase 3 Clinical Trial ... - Smarter Analyst
06/17/16 10:15 AMAERIE PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
06/16/16 09:55 AMAerie Pharma stays on track with late-stage trial enrollment -
06/16/16 08:55 AMAerie Completes Enrollment Of Rocket 4 Final Stage Clinical Study Of RhopressaTM 0.02% -

Social

About Aerie Pharmaceuticals

Aerie Pharmaceuticals logoAerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AERI
  • CUSIP:
Key Metrics:
  • Previous Close: $17.54
  • 50 Day Moving Average: $17.74
  • 200 Day Moving Average: $16.02
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $464.24M
  • Beta: 1.33
  • Current Year EPS Consensus Estimate: $-2.69 EPS
  • Next Year EPS Consensus Estimate: $-2.44 EPS
Additional Links:
Aerie Pharmaceuticals (NASDAQ:AERI) Chart for Friday, July, 29, 2016